Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04219254 · ClinicalTrials.gov registry record · Phase 1
A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
A Phase 1 study of Solid Tumor, Adult, sponsored by BioInvent International AB.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 197
- Enrollment target
- 20
- Study locations
NCT04219254: Recruiting Phase 1 study of Solid Tumor, Adult, sponsored by BioInvent International AB.
NCT04219254 is a Phase 1 study of Solid Tumor, Adult that is actively recruiting participants, run by BioInvent International AB. The registered enrollment target is 197 participants, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target. The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04219254, a Phase 1 study of Solid Tumor, Adult, is actively recruiting participants, sponsored by BioInvent International AB.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 197 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
Primary Outcome
Assess the safety and tolerability profile of increasing doses of BI-1206, administered IV or SC, in combination with pembrolizumab in subjects with advanced solid tumors
Conditions Studied
Interventions
- DRUG BI1206
Study Locations (20)
Other
- LTD High Technology Hospital Med Center - Batumi
- Israel-Georgian Medical Research Clinic Helsicore - Tbilisi
- Jerarsi Clinic - Tbilisi
- Medizinische Hochschule Hannover - Hanover
- Nationales Centrum für Tumorerkrankungen - Heidelberg
- Universität des Saarlandes - Homburg
- Maria Skłodowska-Curie National Institute of Oncology - Gliwice
- Medical University of Silesia - Katowice
- Instytut Centrum Zdrowia Matki Polki - Lodz
- Institutul Oncologic "Prof. Dr. Ion Chiricuta" - Cluj-Napoca
- Centrul de Oncologie SF Nectarie SRL - Craiova
- Hospital Universitari Dexeus - Barcelona
- Hospital Universitari Vall D´Hebron - Barcelona
- Institut Català d'Oncologia Hospital Duran i Reynals - Barcelona
- Hospital Puerta de Hierro - Majadahonda
California
- University of California Los Angeles - Los Angeles
Colorado
- Sarah Cannon Research Institute - Denver
Minnesota
- HealthPartners Institute - Regions Cancer Care Center, - Saint Paul
Oklahoma
- Oklahoma University , Stephenson Cancer Center - Oklahoma City
Texas
- NEXT Oncology - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2020-06-29 |
| Est. Completion | 2027-11 |
| Phase | Phase 1 |
What NCT04219254 shows while recruiting
NCT04219254 is an interventional study that assigns participants to a tested intervention. The registered 197 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 188-participant average among 72 other Solid Tumor, Adult trials with a reported enrollment target.
The record links to 1 condition, with Solid Tumor, Adult appearing as the primary indexed condition, and to 1 intervention - of which BI1206 is the first listed.
NCT04219254 names 20 study sites across 6 states, led by Other, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT04219254 about?
NCT04219254 is a clinical study titled "A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors". Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
What is the current status of trial NCT04219254?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 197 participants. The study started on 2020-06-29. Estimated completion is 2027-11.
What conditions does trial NCT04219254 study?
This clinical trial studies the following conditions: Solid Tumor, Adult.
What interventions are being tested in trial NCT04219254?
The interventions under investigation include: BI1206 (DRUG).
Who is sponsoring clinical trial NCT04219254?
This trial is sponsored by BioInvent International AB, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04219254 being conducted?
This trial has 20 study locations across California, Colorado, Minnesota, Oklahoma, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor, Adult
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04219254's enrollment target sits among peer trials
197 25th of 72 higher than 48 of 72 other Solid Tumor, Adult trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor, Adult trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
Open-Label, Dose-Escalation With Expansion to Assess the Safety, Tolerability, and PK of TRE-515 in Subjects With Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With Pembrolizumab
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
RECRUITING · Phase 1
-
Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06173778 · 197 participants · Phase 2
Semaglutide for Post-Smoking Cessation Weight Management
- NCT05203328 · 198 participants · NA
Prospective Study to Evaluate High Flow Nasal Cannula With Monitored Anesthesia Care During EBUS Bronchoscopy
- NCT05426967 · 198 participants · NA
rTMS for Military TBI-related Depression
- NCT05561114 · 198 participants · Phase 3
Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI